NCT05781386View on ClinicalTrials.gov

A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

March 6, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Advanced Solid TumorCutaneous T Cell Lymphoma
Interventions
DRUG

SIM1811-03 or in combination with Sintilimab injectiont

"SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)"

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-Sen University Cancer Center, Guanzhou

All Listed Sponsors
lead

Jiangsu Simcere Biologics Co., Ltd

INDUSTRY